Gene Therapy for the Cardiomyopathy of Friedreich’s Ataxia
The purpose of this study is to test the safety of the study drug, which is an adeno-associated virus serotype rh10 gene transfer vector (AAVrh.10hFXN), and see what effects it has to treat the cardiomyopathy associated with Friedreich’s ataxia (FA).The study drug, AAVrh.10hFXN, is a gene transfer vector which uses an adeno-associated virus serotype rh.10 as a vehicle to deliver the FXN gene into heart cells. It is hoped that the study drug will help produce the normal amount of frataxin, and thus return the function of your heart cells and limit the effects of the cardiac disease.
ClinicalTrials.gov Link: clinicaltrials.gov/ct2/show/NCT05302271
About the Study
Eligible Ataxia Types
Type of Study
Clinical Trial Phase
Study Start Date
Estimated Completion Date
IRB Approval #
Weill Cornell Medicine/NHLBI
Department of Genetic Medicine
1305 York Ave, 13th Floor
New York, NY
What does participation in the study entail?
You will be asked to come back to WCM at days 1-4, 7, 10, and 14 after the drug infusion; 1, 3, 6 and 12 months following the infusion. After you complete the 12-month on-site visit, you will have an additional assessment at WCM in year 2 at 3, 6, 9 and 12 months, and years 3-5 once yearly.
What are the potential benefits for participants?
It is hoped that the study drug will help produce the normal amount of frataxin, and thus return the function of your heart cells and limit the effects of the cardiac disease.
What are the potential risks for participants?
The risks will be discussed with you by the study physician.
Is there financial compensation?
Is there travel reimbursement?
Yes. At cost.
Who is eligible?
Patients who have been diagnosed with Friedreich’s Ataxia.
Additional Information or Resources
View Other Research Opportunities
The goal of this study is to learn how breath control for speaking and swallowing is impacted in ataxia. The results of this study will set the foundation to see Read More…